©  SAR, LLC. 2020

Bethesda, MD


SAR is a securities class action (SCA) data analytics software company. SAR actively tracks, monitors, and analyzes all federal SCAs that that allege violations of Section 11, Section 12(a)(2), and Section 15 of the Securities Act of 1933 ("Securities Act") and Section 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act"). 
SAR actively tracks, monitors and analyzes all SCAs that allege violations of the Securities and the Exchange Act without any party making a request to do so.  As a result, SAR is a truly independent asset focused on serving primary insurance carriers, excess and surplus (E&S) insurers, specialized D&O claims professionals and brokers, and specialized counsel to Directors and Officers of U.S. listed companies. 
SAR empowers insurance professionals, established class action and corporate governance counsel with highly-specialized tools in the area of securities class action litigation.  The tools are used to analyze and validate the econometric strength of claims that allege violations the Securities Act and Exchange Act.  SAR provides substantive company-specific analyses of SCA risk, exposure, and maximum damages per share of common stock to quantify a baseline estimate of potential class-wide damages to track claim severity more accurately.

SAR is raising the standards. Future-proof public company complex claims and D&O SCA risk with robust event study analysis to quantify exposure and severity in today's high frequency event-driven SCA environment.

The econometric analyses applied to evaluate SCA claims, quantify exposure, and estimate a baseline estimate of potential aggregate damages are based on the proven and court-accepted event study methodology that abides by established case precedents in key circuits of the U.S. Federal Court system.  SAR does not apply any machine learning algorithms or artificial intelligence to perform event study analyses for Exchange Act and Securities Act claims filed against U.S.-listed corporations or to estimate potential SCA exposure from high-risk adverse events that have materialized during the applied evaluation period.